Aptamer Applications

Aptamer Biosensors-Point of Care

2010 Conference on Global Health Diagnostics
“GHDx Innovations Summit: Translating Ideas into Impact”
Paul Yager, Professor of Bioengineering, University of Washington
“Microfluidics 2.0″: Point-of-Care Diagnostics for the Developed and Developing World” http://www.youtube.com/watch?v=rXtuf_8dx9o&feature=related

Using tuberculosis as a model disease, Jonathan Blackburn and colleagues aim to develop a low-cost, hand-held biosensor that combines the selectivity of antigen-specific DNA aptamers with the exceptional specificity of Surface Enhanced Raman Spectroscopy in order to reliably quantify pathogen biomarkers present in patient specimens at the point-of-care, http://www.youtube.com/watch?v=IUfVHE42THQ

Aptamer-based biosensors, Shiping Song, Lihua Wang, Jiang Li, Jianlong Zhao, Chunhai Fan, Trends in Analytical Chemistry, Vol. 27, No. 2, 2008 http://www.sinap.ac.cn/english/text/TrAC.pdf

A collection of papers in Sensors2012 utilizing aptamers http://www.mdpi.com/search?q=aptamer&journal=sensors&volume=&authors=&section=&issue=&article_type=&special_issue=&page=&search=Search

Fujitsu DNA Biosensor Technology http://www.youtube.com/watch?v=llGJY23Ck4U&feature=related


Aptamer Diagnostics

The OTA-Sense System represents a breakthrough in diagnostics cost and performance. This system represents the first global commercial application of an aptamer based detection platform. In this video we provide a step by step description of the use of the use of this system to obtain HPLC quality results with speed and cost comparable to ELISA analysis for ochratoxin A determination. Other products include ultra-fast cleanup columns for HPLC analysis of mycotoxins, including ochratoxin A in grain, wine and beer, and aflatoxins in grain (corn and peanuts), nuts, and aflatoxin M1 in milk http://www.youtube.com/watch?v=jjDW7cmCbeE

CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2, Fang Chen#, Yilan Hu, Dongqing Li, Haidan Chen, Xiao-Lian Zhang, PLoS ONE 4(12): e8142. doi:10.1371/journal.pone.0008142 http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0008142

Discrimination of Recombinant from Natural Human Growth Hormone Using DNA Aptamers, John G. Bruno,* Maria P. Carrillo, Taylor Phillips, and Allison Edge. J Biomol Tech. 2011 April; 22(1): 27–36. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059541/


Nanosensors in cells

Many animal and human diseases are caused by malfunction of metabolic or signal pathways. One example is neurodegenerative diseases such as Parkinsons, which apparently involve the improper function of glutamate, the predominant excitatory neurotransmitter. A recent study using glutamate nanosensors showed that glutamate fluxes can be monitored live in neurons. Furthermore, a precise knowledge of pH in the endocytotic pathway in cancer cells provides an opportunity for developing drug delivery systems for cancer treatment, where the drop in pH after receptor mediated cell internalization can be exploited as a site-specific trigger of drug release. Reactive oxygen species, ROS, are involved in a variety of diseases and represent a third example where the development of anti-oxidant therapeutics could benefit from in vivo monitoring of ROS. Finally, targeted fertilization of crop plants is a biotechnological prerequisite for a modern, efficient and sustainable agriculture. Also this goal would benefit from a toolbox of intracellular nanosensors that can support basic and applied science. Suitable nanosensors will allow to pinpoint the tissues responsible for nutrient uptake and to test the effects of changed fertilizer formulations and applications. http://www.cbio.dk/LiMeS/


Aptamers as Therapeutics

Macugen the first approved aptamer therapeutic, it is for treatment of wet age-related macular degeneration (AMD) http://www.macugen.com/

An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice. Lee YJ, Han SR, Kim NY, Lee SH, Jeong JS, Lee SW. Gastroenterology. 2012 Jul;143(1):155-165.e8. Epub 2012 Mar 28 http://www.ncbi.nlm.nih.gov/pubmed/22465431

Developing aptamers into therapeutics, Rebekah R. White, Bruce A. Sullenger, and Christopher P. Rusconi. J Clin Invest. 2000 October 15; 106(8): 929–934. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC314350/

Aptamers : The New Frontier In Drug Development? Larry Gold article from 2007 http://www.biotechnologyhealthcare.com/journal/fulltext/4/2/BH0402031.pdf

Aptamer Therapeutics: The 21st Century’s Magic Bullet of Nanomedicine, Sarah Shigdar, Jasmina Luczo, Ming Q. Wei, Richard Bell, Andrew Danks, Ke Liu and  Wei Duan. The Open Conference Proceedings Journal, 2010, 1, 118-124. http://www.benthamscience.com/open/toprocj/articles/V001/118TOPROCJ.pdf

Cell-Specific Aptamers as Emerging Therapeutics, Review Article. Cindy Meyer, Ulrich Hahn, and Andrea Rentmeister, Journal of Nucleic Acids Volume 2011 (2011), Article ID 904750, 18 pages. http://www.hindawi.com/journals/jna/2011/904750/


The First Aptamer-Apheresis Column Specifically for Clearing Blood of β1-Receptor Autoantibodies-Application of immunoapheresis to eliminate pathogenic autoantibodies targeting the second extracellular loop of the β1-receptor (β1-AABs) is currently investigated in patients with cardiomyopathy. Aptamers (single short DNA or RNA strands) are a new class of molecules that bind to a specific target molecule. This property qualifies aptamers for potential use in the apheresis technique. We recently identified an aptamer that specifically binds to β1-AABs, so in the present study we tested whether this aptamer could be used as a binder to prepare an apheresis column suitable for clearing β1-AABs from rat’s blood.http://www.diabetes-karlsburg.de/downloads/Circulation-J-Apheresis-paper_2012.pdf

Rss feed from several separation journals http://chromatography.jiriurban.cz/?s=aptamer


Copyright © 2018 The Aptamer Lounge - This site sponsored and maintained by Base Pair Biotechnologies. Site design by ActiveEdge